The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress.
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Asieris Pharmaceuticals; Astellas Pharma; Biological Dynamics; Bristol-Myers Squibb; CG Oncology; Eisai; EnGeneIC; FerGene; Imagin Medical; Incyte; Janssen; Medac; Merck; Photocure; Protara Therapeutics; Roche; Seagen; Sesen Bio; Theralase; TMC Innovation; Urogen pharma; US Biotest
Research Funding - Adolor; Bristol-Myers Squibb; FKD Therapies; Heat Biologics; Janssen/Taris; Merck; NIH; Patient-Centered Outcomes Research Institute (PCORI); Photocure; Seagen; SWOG; Taris BioMedical; The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday
 
Gary D. Steinberg
Stock and Other Ownership Interests - CG Oncology; Epivax Therapeutics; Urogen pharma
Honoraria - Aduro Biotech; AstraZeneca; Bristol-Myers Squibb; CG Oncology; enGene; Epivax Oncology; fergene; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Janssen Oncology; MDxHealth; Merck; Pfizer; Photocure; Roche/Genentech; Seagen; Sesen Bio; Urogen pharma
Consulting or Advisory Role - Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; Imvax; MDxHealth; Merck; NanOlogy; Natera; Nonagen Bioscience; photocure; Roche/Genentech; Taris BioMedical; Verity Pharmaceuticals
 
Brant Allen Inman
Consulting or Advisory Role - Biom'Up; Boston Biomedical; Istari; Seagen; Urogen pharma
Research Funding - FKD Therapies (Inst); Genentech/Roche (Inst); Istari (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); QED Therapeutics (Inst); Taris BioMedical (Inst)
 
Max R. Kates
Honoraria - Astellas Pharma
Consulting or Advisory Role - Astellas Pharma; Genesis Biotechnology Group; Nanology; pacific edge; photocure
 
Edward M. Uchio
Research Funding - Ambry Genetics; Bayer; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Exact Sciences; GenomeDx; Genomic Health; Janssen Oncology; Merck; Merit Medical Systems; Myovant Sciences; Myovant Sciences; Myriad Genetics; Pfizer; Seagen; Veracyte
(OPTIONAL) Uncompensated Relationships - Bayer; Genomic Health; Janssen Oncology; Merck; Myriad Genetics; Pfizer
 
Sima P. Porten
Honoraria - photocure
Consulting or Advisory Role - Bristol-Myers Squibb; KDx Diagnostics; Photocure; Protara Therapeutics
Research Funding - Photocure (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Morgan Roupret
Consulting or Advisory Role - Arquer Diagnostics; GlaxoSmithKline; Intuitive Surgical; Ipsen; Janssen-Cilag; Lilly; MSD; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - Astellas Pharma; Coloplast
 
Joan Redorta
Consulting or Advisory Role - Arquer diagnostics; AstraZeneca; BMS; Combat Medical; Janssen
 
James W.F. Catto
Honoraria - Abbott Laboratories
Consulting or Advisory Role - AstraZeneca/MedImmune; Ferring; Janssen; Roche
Speakers' Bureau - ASCO; AstraZeneca/MedImmune; MSD Oncology; Nucleix; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - European Association of Urology
 
Girish S. Kulkarni
Honoraria - Abbvie; AstraZeneca Canada; Bayer; BioSyent; Knight Pharmaceuticals; Tersera
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Ferring; Janssen Oncology; Merck; Theralase; Verity Pharmaceuticals
 
Thomas Powles
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Mark Tyson
No Relationships to Disclose
 
Gabriel P. Haas
Employment - Astellas Pharma
 
Yao Yu
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Matthew Birrenkott
Employment - Seagen
 
Yair Lotan
Stock and Other Ownership Interests - C2i genomics; CAPs medical; Nanorobotics; Vessi Medical
Consulting or Advisory Role - Abbvie; Ambu; AstraZeneca; Aura Biosciences; BMS; C2i genomics; caps medical; Cleveland Diagnostics; Convergent Genomics; Fergene; Merck; Nanogen Biopharmaceutical; Nanorobotics; Nucleix; pacific edge; Photocure; Seagen; Stimit; Urogen pharma; verity pharmaceuticals; Vessi Medical; virtuoso surgical; Xcures
Research Funding - Abbott Molecular (Inst); Augmenix; BioCancell (Inst); Cepheid; Cepheid (Inst); GenomeDx (Inst); MDxHealth (Inst); pacific edge; pacific edge (Inst); Photocure (Inst); storz (Inst)